EUVIMEDEUVIMED entdecken
Open Access

Impact of Specialized Treatment Setting on Survival in Adolescent and Young Adult ALL

Lori S Muffly iD, Helen M Parsons iD, Kate Miller iD, Qian Li iD, Ann Brunson iD, Theresa H Keegan iD

JCO Oncology Practice · 2023-12 · 19 (12) · 1190-1198

DOI: 10.1200/op.23.00373 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Oncology Practice, 2023-12. Verfasst von Lori S Muffly und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University, Stanford, CA. Hauptthemen laut MEDLINE: Survival Rate, Precursor Cell Lymphoblastic Leukemia-Lymphoma. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NCCDPHP CDC HHS, NIDA NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Unlike children with ALL who receive cancer care primarily at specialized cancer centers (SCCs; National Cancer Institute and/or Children's Oncology Group centers), adolescents and young adults (AYAs; 15-39 years) receive care in a variety of settings. Using population-based data, we describe where AYAs with ALL receive treatment and determine associations with overall survival (OS). METHODS Data from the 2004 to 2018 California (CA, n = 2,283), New York (NY, n = 795), and Texas (TX, n = 955) state cancer registries were used to identify treatment setting of AYAs with newly diagnosed ALL. Multivariable Cox proportional hazards regression models evaluated associations with OS. RESULTS Seventy percent were older than 18 years, and 65% were male. A majority in CA (63%) and TX (64%) were Hispanic while most in NY were non-Hispanic White (50%). Treatment at an SCC occurred in 48.2% (CA), 44.4% (NY), and 19.5% (TX). Across states, AYAs who were older or uninsured were less likely to receive treatment at an SCC. Treatment at an SCC was associated with superior OS in CA (hazard ratio [HR], 0.73; 95% CI, 0.63 to 0.85) and TX (HR, 0.61; 95% CI, 0.45 to 0.83); a nonsignificant association was seen in NY (HR, 0.83; 95% CI, 0.64 to 1.08). CONCLUSION Only 20%-50% of AYA patients with ALL received frontline treatment at SCCs. Treatment of ALL at an SCC was associated with superior survival, highlighting the importance of policy efforts to improve access and reduce inequities in AYA ALL care.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Survival RatePrecursor Cell Lymphoblastic Leukemia-LymphomaAdolescentFemaleHumansMaleYoung AdultMedically UninsuredProportional Hazards ModelsAdult

Autor:innen und Institutionen

  • Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University, Stanford, CA.
  • Division of Health Policy and Management, University of Minnesota School of Public Health, Minneapolis, MN.
  • Quantitative Sciences Unit, Stanford University, Stanford, CA.
  • Division of Hematology/Oncology, University of California Davis, Davis, CA.

ORCID-Profile: Lori S Muffly, Helen M Parsons, Kate Miller, Qian Li, Ann Brunson, Theresa H Keegan

Förderung

  • NCI NIH HHS
  • NCCDPHP CDC HHS
  • NIDA NIH HHS
  • NHLBI NIH HHS

Zitieren

APA

Muffly, L. S., Parsons, H. M., Miller, K., Li, Q., Brunson, A., & Keegan, T. H. (2023). Impact of Specialized Treatment Setting on Survival in Adolescent and Young Adult ALL. JCO Oncology Practice, 19(12), 1190-1198. https://doi.org/10.1200/op.23.00373

Vancouver

Muffly LS, Parsons HM, Miller K, Li Q, Brunson A, Keegan TH. Impact of Specialized Treatment Setting on Survival in Adolescent and Young Adult ALL. JCO Oncology Practice. 2023;19(12):1190-1198. doi:10.1200/op.23.00373

BibTeX
@article{Muffly2023,
  author = {Muffly, Lori S and Parsons, Helen M and Miller, Kate and Li, Qian and Brunson, Ann and Keegan, Theresa H},
  title = {Impact of Specialized Treatment Setting on Survival in Adolescent and Young Adult ALL},
  journal = {JCO Oncology Practice},
  year = {2023},
  volume = {19},
  number = {12},
  pages = {1190--1198},
  doi = {10.1200/op.23.00373}
}
Kostenlos starten →